AQUESTIVE THERAPEUTICS INC

Julie Krop’s 10(b)(5)(1) buy‑sell move shows disciplined liquidity management and long‑term confidence in AQUESTIVE’s CNS therapeutics pipeline.

CEO Barber Daniel sells 25k shares of AQT at $4.16 – insider trades hint at liquidity needs but long‑term confidence in this biotech’s pipeline.

Insider buying spurs bullish outlook for Aquestive, with senior execs securing 50,500 stock options—signaling confidence in the company’s CNS pipeline and future growth prospects.

Insightful insider sales at Aquestive Therapeutics reveal routine equity management, yet the company’s bullish pipeline and 89.5% YTD rally signal cautious optimism for investors.